Skip to content Skip to main menu Skip to utility menu

Drug safety notice: Thiamine Hydrochloride 100mg in 1ml IV and Tenecteplase 25mg powder solution for injection

September 5, 2024

Thiamine Hydrochloride 100mg in 1ml IV (to replace Pabrinex IV shortage)

Problem:

  • Pabrinex supplies will not be available indefinitely once current reserves run out.
  • There are no other licensed parenteral alternatives to Pabrinex intravenous and intramuscular injections.
  • Thiamine hydrochloride IV (Thiamine IV) is an unlicensed alternative to Pabrinex for the two indications outlined below (alcohol dependency and preventing refeeding syndrome).

Please see full safety notice including advice, clinical information, dosing and key resources here.

Please see the leaflet for Thiamine Hydrochloride here.

Tenecteplase 25mg powder for solution for injection

Problem:

  • Last Alteplase allocations will be issued August 2024.
  • This is due to the arrival of Tenecteplase (Metalyse) 25mg which will become the default option for stroke treatment.
  • Supplies of alteplase will be difficult to obtain while there is no allocation available.

Please see full safety notice including advice, actions and resources here.